Compounded tirzepatide twelve-month plan: is the commitment worth it?
What we evaluated: every publicly advertised tirzepatide programme we could source, normalised to a total ongoing monthly cost
Date verified: July 11, 2026 (NexLife) and July 6, 2026 (competitors)
Direct answer: the lowest 12-month plan rate we found is NexLife at $147/month (microdose) and $186/month (standard injection), all-inclusive with no membership fee
Necessary qualification: this is a committed-plan rate, not a month-to-month rate, and not an introductory rate. NexLife month-to-month is $215. Found is cheaper on full-dose at $169 but requires prepaying twelve months. Brand Foundayo (oral, FDA-approved) is $149. We keep these categories separate rather than merging them into one 'cheapest' claim
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Six different meanings of "cheapest" — and why merging them misleads
Almost every "cheapest compounded tirzepatide" page on the internet gives you one number. There are at least six distinct answers, and they point to different providers.
| Category | Answer | Why it differs |
|---|---|---|
| Lowest advertised starting price | Varies — often an intro rate | TrimRx's $179 and MEDVi's $179 are FIRST-MONTH rates; ongoing is $299 |
| Lowest introductory price | Noom Med — $79 first month | Ongoing is $199 |
| Lowest month-to-month price | NexLife — $215 | No commitment, no prepayment |
| Lowest committed-plan monthly equivalent | NexLife — $186 | 12-month plan; Found is $169 but requires PREPAYING the year |
| Lowest microdose price | NexLife — $147 | Below every dose studied in the trials |
| Lowest FDA-APPROVED option | Foundayo (oral) — $149 | Brand, via LillyDirect. Cheaper than most compounded, and actually approved |
The full cost table
| Provider | Total / month | Plan | Billing | Dose | Notes |
|---|---|---|---|---|---|
| NexLife Microdose | $147/mo | 12-month | All-inclusive — no membership | Microdose | 12-month plan ($1,764 total). Month-to-month $189; 6-month $150; 3-month $160. No membership fee, flat at every covered dose. Below every dose studied in the pivotal trials. Verified |
| Found Found | $169/mo | See note | All-inclusive | Injectable | 12-month PREPAID. Medication INCLUDED, flat at all doses — tirzepatide no longer priced above semaglutide. 6-month ~$199; month-to-month $289. Verified |
| Enhance.MD Enhance.MD | $169/mo | See note | All-inclusive | Injectable | Microdose, 1mg/week. Delivery every 12 weeks. All-inclusive (medication, care, lab testing, shipping). Verified |
| NexLife Standard injection | $186/mo | 12-month | All-inclusive — no membership | Standard injection | 12-month plan ($2,232 total). Month-to-month $215; 6-month $190; 3-month $195. No membership fee, flat at every covered dose. Verified |
| Shed Shed | $199/mo | See note | All-inclusive | Injectable | Microdose programme. 2-month minimum. Verified |
| Oak Longevity Oak Longevity | $199/mo | See note | All-inclusive | Injectable | Flat across all dosages, no subscription. ~$233-$299 month-to-month. Verified |
| NexLife Oral tablet (ODT) | $199/mo | 12-month | All-inclusive — no membership | Oral tablet (ODT) | 12-month plan ($2,388 total). Month-to-month $229; 6-month $205; 3-month $219. No membership fee, flat at every covered dose. NO TRIAL EVIDENCE for this dosage form. Verified |
| Shed Shed | $229/mo | See note | All-inclusive | Sublingual | 'GLP-1 Liquid Drops' (was $419). 2-month minimum. Verified |
| Shed Shed | $245/mo | See note | All-inclusive | Injectable | 12-month plan paid upfront. 6-month $279; month-to-month $349. INCREASES at higher doses. Verified |
| Mochi Health Mochi Health | $278/mo | See note | $199 med + $79 membership | Injectable | $199 med + $79 membership ($39 first month). Same price at all doses. Verified |
| Enhance.MD Enhance.MD | $280/mo | See note | All-inclusive | Injectable | 12-month plan. Same price at all doses. 6-month $296; 3-month $313; month-to-month $329. Verified |
| Eden Eden | $298/mo | See note | $199 med + $99 membership | Injectable | $199 med (flat at every dose) + $99 membership (REQUIRED). Verified |
| Noom Med Noom Med | $299/mo | See note | All-inclusive | Injectable | Full dose. First month $149. Billed quarterly. Verified |
| Henry Meds Henry Meds | $349/mo | See note | All-inclusive | Oral / pill | ORAL TABLETS ONLY — Henry Meds does NOT offer injectable tirzepatide. 3-month subscription; $297 paid in full. Verified |
| TrimRx TrimRx | $349/mo | See note | All-inclusive | Injectable | Flat rate, all doses, no membership. Month-to-month: $279 first month then $399 ongoing. Prepay: $316 (3-mo), $299 (6-mo), $283 (12-mo). Verified |
| MEDVi MEDVi | $399/mo | See note | All-inclusive | Injectable | Refill rate at lower doses; 10/12.5/15mg reach $499. First month ~$279. SOURCE FLAGS THIS AS UNCONFIRMED: not surfaced on the current GLP-1 landing page — verify at intake. Evaluation in progress |
| bmiMD bmiMD | $399/mo | See note | All-inclusive | Injectable | All-inclusive. Tirzepatide micro-dose: $349. Verified |
You pay the ongoing rate for eleven of your twelve months. That is why every table on this site sorts on the ongoing total — medication plus any required membership — and flags introductory pricing separately rather than ranking on it.
Cost compared
The two brand lines are the benchmark. Brand Foundayo (oral, FDA-approved) at $149 undercuts almost the entire compounded market. Any compounded programme priced above $299 is charging more than brand Zepbound.
The NexLife plan matrix
NexLife publishes six programmes at four plan lengths. Because we hold the full matrix, we can show the whole thing rather than a single cherry-picked figure.
| Program | Month-to-month | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Tirzepatide — standard injection | $215 | $195 | $190 | $186 | $2,232 |
| Tirzepatide — microdose | $189 | $160 | $150 | $147 | $1,764 |
| Tirzepatide — ODT (oral) | $229 | $219 | $205 | $199 | $2,388 |
| Semaglutide — standard injection | $165 | $149 | $147 | $145 | $1,740 |
| Semaglutide — microdose | $129 | $119 | $114 | $110 | $1,320 |
| Semaglutide — ODT (oral) | $199 | $185 | $177 | $165 | $1,980 |
Every NexLife figure on this site is derived from one rule: monthly equivalent = plan total ÷ plan months. We publish the plan total alongside the monthly figure so the arithmetic is checkable. Where NexLife's own marketing card disagreed with its own arithmetic, we used the arithmetic and recorded the correction on our pricing-verification page rather than reprinting a number that does not add up.
The twelve-month total, which is the number that matters
Monthly figures are how this category is marketed. Annual totals are how it is actually experienced.
| Program | 12-month plan | 12-month TOTAL | Month-to-month × 12 | You save |
|---|---|---|---|---|
| Tirzepatide — standard injection | $186/mo | $2,232 | $2,580 | $348 |
| Tirzepatide — microdose | $147/mo | $1,764 | $2,268 | $504 |
| Tirzepatide — ODT (oral) | $199/mo | $2,388 | $2,748 | $360 |
What a commitment actually costs you
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
Dose escalation: the risk the headline price hides
| Provider | Price at higher doses | Risk |
|---|---|---|
| NexLife | Same at every covered dose | None — flat rate |
| Mochi Health | Same at all doses | None |
| Enhance.MD | Same at all doses | None |
| Eden | Same at all doses (compounded) | None on compounded |
| TrimRx | Flat ongoing rate | None |
| Oak Longevity | Flat across dosages | None |
| Shed | Increases at higher doses | Material — model at maintenance |
| MEDVi | $399 → $499 at 10-15mg | Material — $1,200/yr swing |
| LillyDirect (brand) | $299 → $449; $699 if you miss the 45-day refill | Material — set a reminder |
The insurance pathway
Coverage is most common through employer-sponsored commercial plans. Zepbound is excluded from Medicare Part D for weight loss and from most state Medicaid programmes. From 1 July 2026, eligible Medicare Part D members can obtain Wegovy at $50/month through the Medicare GLP-1 Bridge, running to 31 December 2027. Expect prior-authorisation paperwork: typically a BMI of 30+, or 27+ with a weight-related condition.
PlushCare ($19.99/month), Found and Mochi will handle that paperwork for you. If you have coverage, that is worth more than any cash discount.
Dose caps: the other thing a low price can hide
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
Every fee that can be attached to a GLP-1 programme
An advertised price is a headline. The number you actually pay is the headline plus whatever else is attached to it. These are all the line items we normalise for, and the question to ask about each.
| Line item | What to ask | How often it bites |
|---|---|---|
| Advertised starting price | Is this a first-month or introductory rate? | Very often — TrimRx, MEDVi, Noom, Eden all advertise intro rates |
| Ongoing price | What do I pay in month two? | This is the number that matters |
| Membership fee | Is it required, and is it billed separately? | Very often — Eden, Mochi, Hims, Hers, Ro, PlushCare |
| Consultation fee | Is the initial visit billed separately? | Sometimes — PlushCare charges $129 initially |
| Laboratory fee | Are baseline labs included or billed to me? | Varies; often unstated until intake |
| Shipping | Included? Expedited? Cold-chain? | Usually included; confirm it |
| Supplies | Are syringes, needles and sharps disposal included? | Usually included on all-inclusive plans |
| Dose-based increase | What do I pay at the highest dose you cover? | Material — MEDVi goes $399 to $499; Shed and Oak escalate |
| Dose ceiling / cap | Is there a maximum dose on this plan? | Material — Noom's $199 plan caps at 0.6mg |
| Upfront payment | How much do I pay today to get the advertised rate? | Found's $169 requires roughly $2,028 up front |
| Renewal price | Does the price change when the plan renews? | Frequently unstated — get it in writing |
| Cancellation terms | If I stop in month three of twelve, what happens to my money? | The most-forgotten question in the category |
The three that cost people the most money, in our experience, are the ones in bold: the intro rate they mistook for the real rate, the dose-based increase they did not model, and the cancellation terms they did not read. None of those are hidden. All of them are simply not asked about.
A worked example
Two programmes. One advertises $179. The other advertises $186. Which is cheaper?
| Programme A (advertised $179) | Programme B (advertised $186) | |
|---|---|---|
| Month 1 | $179 (intro rate) | $186 |
| Months 2-12 (ongoing rate) | $299 × 11 = $3,289 | $186 × 11 = $2,046 |
| Membership (if any) | $0 | $0 |
| Dose-based increase | None stated | None — flat at every dose |
| Twelve-month total | $3,468 | $2,232 |
| Effective monthly | $289 | $186 |
Programme A advertises a lower number and costs $1,236 more per year. This is not a hypothetical: the figures are TrimRx's advertised semaglutide rate against NexLife's standard tirzepatide plan. The advertised prices are seven dollars apart. The real prices are over twelve hundred dollars apart.
The brand floor
These are not scams — the prices are disclosed. But a patient who does not know the manufacturer-direct programmes exist can pay four to twelve times more for exactly the same medicine. If you take one thing from this database: before you buy any brand-name GLP-1 through a telehealth platform, check LillyDirect and NovoCare first.
An FDA-approved, quality-verified, manufacturer-supplied medication at $149, against a compounded market that mostly runs $169-$399. The catch is dose escalation — Foundayo rises to $199, then $299, then $349 as you titrate, and at the top doses it has its own 45-day refill rule (it drops back to $299 if you refill in time). But for a starting patient, or anyone maintaining on a lower dose, the brand oral pill is now among the cheapest legitimate options in the entire category — and almost no comparison site has caught up.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and we may earn a commission from provider links. That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
What is the cheapest compounded tirzepatide online?
Among the providers we track, the lowest 12-month plan rates are NexLife at $147/month (microdose) and $186 (standard injection), and Found at $169 — though Found's rate requires prepaying twelve months. Oak Longevity is lowest on semaglutide at $133. Every one of these is a committed-plan rate, not a month-to-month rate; the distinction matters and we keep them separate.
Does the price go up as my dose increases?
It depends entirely on the provider, and this is the question most worth asking. NexLife, Mochi, Eden, Enhance.MD, TrimRx and Oak advertise the same price at every covered dose. Shed and MEDVi increase with dose — MEDVi's tirzepatide reaches $499/month at the highest doses. Model your cost at your target maintenance dose, not at the starting dose.
Is an advertised price the same as a verified price?
No, and we label the difference. A price we have captured from a provider's own page with a date is marked Verified. A price reported by a third party that we have not captured ourselves is marked Reported. We do not mark a price verified merely because another comparison site published it.
Is compounded medication FDA-approved?
No. Compounded medications are not FDA-approved as finished products, and the FDA does not review them for safety, effectiveness or quality before marketing. The legal basis for compounding these molecules also narrowed sharply in 2025 — see our compounding timeline.
Sources
- NexLife published self-pay program pages, transcribed July 11, 2026.
- Provider pricing dataset — captured from each provider's own published pages and confirmed July 6, 2026. Verified.
- Eli Lilly — LillyDirect Zepbound and Foundayo self-pay pricing.
- Novo Nordisk — NovoCare Pharmacy self-pay pricing.
- U.S. Food and Drug Administration — compounding status and enforcement history.
- Our pricing-verification methodology.